Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma.

Clin Med Insights Oncol · 2022 · PMC9520173 · PMID 36186672

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In addition, a retrospective study evaluating anti-PDL1 therapy in FGFR+ and FGFR– patients showed a trend toward lower ORR and disease control rate in FGFR+ patients in comparison with FGFR– patients who had received anti-PDL1 therapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.